Why compare them?
These records are compared to clarify how their mechanisms, research areas, and evidence maturity differ.
Simple first. Deeper when you want it.
Understand the differences that matter.
See the biggest similarities, differences, strengths, limitations, and unanswered questions first—then open the evidence behind them.
Compound comparison
5-Amino-1MQ vs. Liraglutide
Understand the meaningful overlap, differences, evidence, and unknowns—then go deeper only when you want to.
60-Second Summary
The answer first
Current evidenceComparable evidence base
No direct head-to-head study is represented. This comparison uses separate evidence records that may differ in population, duration, route, dose, and endpoint.
✓ Shared
Shared Similarities
- Both are included in the Relay research library, but their current records answer substantially different questions.
⇄ Different
Biggest Difference
5-Amino-1MQ is distinguished by 5-Amino-1MQ is a small-molecule enzyme inhibitor—not a peptide, receptor agonist, NAD+ product, or nicotinamide precursor; Liraglutide is distinguished by single GLP-1 receptor agonist with once-daily approved injection products and a long human evidence record.
? Unknown
Biggest Unknown
No direct head-to-head study establishes how these compounds compare under the same population, dose, duration, and endpoints.
Key Takeaways
5-Amino-1MQ is distinguished in the current record by 5-Amino-1MQ is a small-molecule enzyme inhibitor—not a peptide, receptor agonist, NAD+ product, or nicotinamide precursor. Liraglutide is distinguished by single GLP-1 receptor agonist with once-daily approved injection products and a long human evidence record. Neither is objectively “better”; the useful question is which evidence record addresses the research question being asked.
Research matrix
Which question has stronger current support?
Research questionStronger current supportExplanation
Human evidenceLiraglutide
5-Amino-1MQ: Preclinical evidence only. Liraglutide: Mature human evidence.
Regulatory historyLiraglutide
5-Amino-1MQ: Not FDA approved. Liraglutide: FDA approved for defined product-specific indications.
Mechanistic breadth5-Amino-1MQ
More named targets describes mechanistic breadth; it does not establish greater effectiveness.
Direct comparisonUnknown
Separate studies cannot establish comparative superiority.
Deeper when you want it
Explore the evidence and nuance
Best-studied areas and pathway mapSee shared targets, unique pathways, and the research questions attached to each record.
5-Amino-1MQ
- Body weight and adiposity in obese mice
- Glucose tolerance and insulin sensitivity in mice
- Fatty liver and metabolic dysfunction in mice
- Aged muscle regeneration and strength in mice
Liraglutide
- Weight management
- Type 2 diabetes
- Cardiovascular outcomes
- Adolescent obesity
Pathway and research map
Shared foundation and unique questions
Research confidence by questionCompare regulatory, human-evidence, outcome, and administration records side by side.
Question by question
What each evidence base can actually answer
Regulatory statusEvidence, not a winner
5-Amino-1MQNot FDA approved
Not FDA approved. FDA stated in a January 2026 warning letter that 5-amino-1-methylquinolinium iodide was not eligible for 503B compounding under the circumstances described.
LiraglutideFDA-labeled indications
FDA approved in product-specific daily injection formulations for chronic weight management, type 2 diabetes, and cardiovascular-risk reduction in a defined diabetes population.
Evidence depthEvidence, not a winner
5-Amino-1MQCells + mice only
Repeated adipocyte and mouse metabolic findings, two aged-mouse muscle studies, a cancer-cell study, and a bladder-cancer mouse model. Human tumor profiling studied NNMT biology, not 5-Amino-1MQ treatment.
LiraglutideMature Phase 3 + outcomes
Multiple randomized Phase 3 trials and the 9,340-participant LEADER cardiovascular outcomes trial, with adult and pediatric product-specific evidence.
Weight outcomesEvidence, not a winner
5-Amino-1MQMouse signal only
Two diet-induced-obesity mouse studies reported lower body weight or weight gain and less fat mass without lower food intake. No human weight-loss evidence was located.
LiraglutidePeer-reviewed Phase 3
SCALE reported −8.4 kg mean change at 56 weeks versus −2.8 kg placebo. STEP 8 directly compared liraglutide 3.0 mg with semaglutide 2.4 mg.
Type 2 diabetesEvidence, not a winner
5-Amino-1MQMouse signal only
A 28-day mouse study reported better glucose tolerance, insulin sensitivity, and hyperinsulinemia measures. No human diabetes-efficacy evidence was located.
LiraglutideApproved + pediatric trial
Victoza has extensive adult evidence and controlled pediatric evidence beginning at age 10. Product-specific labeled doses differ from weight-management use.
Obstructive sleep apnoeaEvidence, not a winner
5-Amino-1MQNo dedicated evidence
No controlled human or dedicated preclinical obstructive-sleep-apnoea evidence was located.
LiraglutideControlled study; not approved
A 359-participant trial found a larger reduction in apnea–hypopnea index than placebo, but no U.S. liraglutide OSA indication was identified.
Cardiovascular outcomesEvidence, not a winner
5-Amino-1MQNo outcomes evidence
No human cardiovascular-outcomes program was located. Mouse metabolic markers are not cardiovascular event evidence.
LiraglutideLEADER + labeled use
LEADER found fewer major cardiovascular events in adults with type 2 diabetes and high cardiovascular risk, supporting a defined Victoza indication.
Administration and handlingEvidence, not a winner
5-Amino-1MQAnimal protocols only
Published animal studies used different subcutaneous, oral, and intravenous exposures. Poor oral bioavailability was reported in mice; no human route, dose, cycle, reconstitution, or storage standard exists.
LiraglutideDaily product-specific injection
Current approved products are once-daily subcutaneous, ready-to-use solutions. Saxenda and Victoza have different labeled dose ranges, purposes, and instructions.
Comparison limitationsUnderstand what this comparison cannot establish before interpreting separate studies.
Comparable evidence base
- No direct head-to-head trial is represented for this pair.
- Separate studies may use different populations, endpoints, durations, doses, routes, and estimands.
- Results should not be interpreted as comparative superiority or individual guidance.
Current unknowns
Questions the evidence cannot answer yet
- Human pharmacokinetics, safety, tolerability, interactions, dose-response, and whether any mouse metabolic or muscle signal translates into clinical benefit.
- Long-term comparative outcomes versus newer weekly incretin therapies and whether narrower research findings become approved uses.
Community Intelligence
Emerging patterns, clearly separated from evidence
5-Amino-1MQ
No community experiences yetBe the first account holder to contribute.
Liraglutide
No community experiences yetBe the first account holder to contribute.
Community Intelligence summarizes structured, self-reported experiences. It can reveal patterns and useful research questions, but it cannot prove safety, effectiveness, or cause and effect. Published evidence is always shown separately.